TP53 and precursor B-cell acute lymphoblastic leukemia: For example, the MDM2 inhibitors have previously been shown to exert tumor suppression and the activation of apoptotic pathways by interfering with its interaction with p53 in B-Acute Lymphoblastic Leukemia [60].